Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Zender

Showing results (11-20 of 192) with videos related to

Pageof 20
Sort By:
Current Opinion in Oncology|November 29, 2007
Integrative oncogenomic approaches for accelerated cancer-gene discoveryLars Zender, Scott W Lowe
Aging|February 17, 2010
Keeping your senescent cells under controlLars Zender, K Lenhard Rudolph
British Journal of Cancer|July 24, 2021
Exploiting lipotoxicity for the treatment of liver cancerRamona Rudalska, Lars Zender, Daniel Dauch
Cancer Cell|June 12, 2019
The Worst from Both Worlds: cHCC-ICCMarco Seehawer, Luana D'Artista, Lars Zender
Cell|May 22, 2007
Snapshot: genetic mouse models of cancerLars Zender, Johannes Zuber, Scott W Lowe
Oncoimmunology|June 28, 2012
Immune surveillance of pre-cancerous senescent hepatocytes limits hepatocellular carcinoma developmentTetyana Yevsa, Tae-Won Kang, Lars Zender
Nature Reviews. Gastroenterology & Hepatology|November 30, 2017
Cellular senescence in gastrointestinal diseases: from pathogenesis to therapeuticsNina Frey, Sascha Venturelli, Lars Zender, et al.
Gastroenterology|June 4, 2013
Primary liver carcinomas can originate from different cell types: a new level of complexity in hepatocarcinogenesisJessica Zucman-Rossi, Jean-Charles Nault, Lars Zender
Carcinogenesis|July 12, 2013
RRM1 domain of the splicing oncoprotein SRSF1 is required for MEK1-MAPK-ERK activation and cellular transformationAriel Shimoni-Sebag, Ilana Lebenthal-Loinger, Lars Zender, et al.
Cell Cycle (Georgetown, Tex.)|September 10, 2013
Changing T-cell enigma: cancer killing or cancer control?Thomas Wieder, Heidi Braumüller, Ellen Brenner, et al.
Pageof 20

Showing results (11-20 of 192) with videos related to

Sort By:
Pageof 20
Current Opinion in Oncology|November 29, 2007
Integrative oncogenomic approaches for accelerated cancer-gene discoveryLars Zender, Scott W Lowe
Aging|February 17, 2010
Keeping your senescent cells under controlLars Zender, K Lenhard Rudolph
British Journal of Cancer|July 24, 2021
Exploiting lipotoxicity for the treatment of liver cancerRamona Rudalska, Lars Zender, Daniel Dauch
Cancer Cell|June 12, 2019
The Worst from Both Worlds: cHCC-ICCMarco Seehawer, Luana D'Artista, Lars Zender
Cell|May 22, 2007
Snapshot: genetic mouse models of cancerLars Zender, Johannes Zuber, Scott W Lowe
Oncoimmunology|June 28, 2012
Immune surveillance of pre-cancerous senescent hepatocytes limits hepatocellular carcinoma developmentTetyana Yevsa, Tae-Won Kang, Lars Zender
Nature Reviews. Gastroenterology & Hepatology|November 30, 2017
Cellular senescence in gastrointestinal diseases: from pathogenesis to therapeuticsNina Frey, Sascha Venturelli, Lars Zender, et al.
Gastroenterology|June 4, 2013
Primary liver carcinomas can originate from different cell types: a new level of complexity in hepatocarcinogenesisJessica Zucman-Rossi, Jean-Charles Nault, Lars Zender
Carcinogenesis|July 12, 2013
RRM1 domain of the splicing oncoprotein SRSF1 is required for MEK1-MAPK-ERK activation and cellular transformationAriel Shimoni-Sebag, Ilana Lebenthal-Loinger, Lars Zender, et al.
Cell Cycle (Georgetown, Tex.)|September 10, 2013
Changing T-cell enigma: cancer killing or cancer control?Thomas Wieder, Heidi Braumüller, Ellen Brenner, et al.
Pageof 20